Drug Profile

TQB 3303

Alternative Names: TQB-3303

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chia Tai Tianqing Pharmaceutical Group
Class Antineoplastics; Small molecules
Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Mar 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (PO, Tablet)
27 Feb 2020 TQB 3303 is available for licensing as of 27 Feb 2020. https://www.cttq.com/en/partner/index.htm
19 Feb 2020 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Solid tumour (Late-stage disease) in China in April 2020 (NCT04275050)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com